Endocrine disorders among long-term survivors of childhood XXXX .

@entity1 @entity135 @entity5 @entity4611 @entity2124
PURPOSE: @entity135 ( @entity135 ) survivors are at increased risk of developing @entity4611 as an adverse event of radiotherapy. Our aim was to investigate the frequency and risk factors for @entity4611 in these survivors. Secondly, we aimed to compare the prevalence of @entity4611 between survivors treated with external beam radiation therapy (EBRT) and survivors treated with the ablative surgery, moulage technique after loading brachytherapy, and surgical reconstruction (AMORE) procedure. METHODS: Eighty @entity135 survivors treated in London (EBRT based) and Amsterdam (AMORE based: AMORE if feasible, otherwise EBRT) in the period 1990-2010 and alive >= 2 years post-treatment were evaluated. Survivors were evaluated in multidisciplinary late-effects clinics, with measurement of linear growth, determination of thyroid function, and @entity2124 parameters. Additional data, such as baseline characteristics, anthropometrics, pubertal stage, and the results of additional laboratory investigations, were retrieved from @entity1 charts. RESULTS: @entity4611 was diagnosed in 24 in 80 (30%) survivors, after a median follow-up time of 11 years. Median time to develop @entity4611 after @entity135 diagnosis was 3.0 years. Risk factors were EBRT-based therapy (odds ratio [OR] 2.06; 95% confidence interval [CI] 1.79-2.46), parameningeal @entity5 site (OR 1.83; 95% CI 1.60-2.17) and embryonal RMS histology (OR 1.49; 95% CI 1.19-1.90). CONCLUSIONS: Radiotherapy used for the treatment of @entity135 confers a significant risk of the development of @entity4611 . AMORE-based treatment in @entity1 with @entity135 resulted in less @entity4611 than treatment with conventional EBRT. Our findings underscore the importance of routine early endocrine follow-up in this specific population.
